Voya Investment Management LLC Trims Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Voya Investment Management LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 36.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,254 shares of the company's stock after selling 25,547 shares during the period. Voya Investment Management LLC owned approximately 0.08% of Janux Therapeutics worth $2,369,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in JANX. Adage Capital Partners GP L.L.C. grew its stake in shares of Janux Therapeutics by 47.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after acquiring an additional 986,750 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock worth $59,429,000 after purchasing an additional 950,557 shares in the last quarter. Rock Springs Capital Management LP acquired a new stake in Janux Therapeutics in the 4th quarter valued at about $10,947,000. Tower Research Capital LLC TRC grew its position in shares of Janux Therapeutics by 878.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after buying an additional 3,436 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky acquired a new stake in Janux Therapeutics in the fourth quarter valued at approximately $653,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. acquired 110,206 shares of Janux Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. This trade represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,001 shares of company stock worth $313,964 over the last 90 days. Company insiders own 29.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on JANX. Scotiabank reduced their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Wedbush reaffirmed an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Janux Therapeutics has an average rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Trading Down 2.1 %

Shares of NASDAQ JANX traded down $0.55 during midday trading on Friday, reaching $25.82. 306,914 shares of the company were exchanged, compared to its average volume of 857,946. Janux Therapeutics, Inc. has a 1 year low of $22.52 and a 1 year high of $71.71. The stock has a fifty day simple moving average of $29.36 and a 200 day simple moving average of $41.93. The stock has a market cap of $1.53 billion, a P/E ratio of -22.07 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.04. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.